Lilly's Cyramza Expands Its RANGE With Bladder Cancer But OS Data Needed

Lilly's Cyramza has become the first product to show an improvement in progression-free survival in previously treated advanced bladder cancer, but the company is waiting to see an overall survival benefit before it takes the data to the regulators.